绝经后乳腺癌术前阿那曲唑新辅助内分泌治疗58例临床效果观察

The Clinic Effect of Neoadjuvant Treatment of Postmenopausal Breast Cancer with Anastrozole Clinical Observation of 58 Cases

目的:探讨对绝经后乳腺癌术前采用阿那曲唑行新辅助内分泌治疗效果观察。方法:选择符合标准的患者在外科手术前12周开始按要求接受阿那曲唑片治疗,并且按计划在治疗前、开始治疗后以及手术切除前测量各项观测指标。结果:58例患者经过3个月的治疗后,超过55%的患者症状得到了部分缓解,完全缓解(CR)均无。手术方式均可进行改良根治手术。可切除率明显改善。术后病理完全缓解(pCR)均无。治疗中所有患者的不良反应程度较轻,药物耐受性均较好。结论:本研究结果表明阿那曲唑用于绝经后乳腺癌术前新辅助治疗时有一定的临床效果,对身体耐受度不高或不愿意接受化疗方式的患者是一个可行的选择方式。

Objective： To investigate the effect of preoperative neoadjuvant endocrine treatment of postmenopausal breast cancer with anastrozole. Methods： The patients were treated with anastrozole lmg once daily from Preoperative 12 weeks to operation. The diameter of tumor was measured by sliding caliper and ultrasound on Preoperative 12 weeks, 8 weeks, 4 weeks and the Preoperative 1 day. In addition the adverse effects that occured in the course of treat- ment were recorded, as well as the changes of patients＇ biochemical parameters including liver/kidney function and blood/urine tests were recorded. Results. Among 58 patients treated with anastrozole for 3 months, more than 55% of the patient＇s symptoms were partially alleviated, but none got complete remission （CR）. But none got the postoperative pathologic complete response （pCR）. The adverse effects were insignificant in all patients and the neoadjuvant endo- crine treatment with anastrozole was well tolerated by all patients. Conclusion： In this study, we could conclude that the preoperative neoadjuvant endocrine treatment of postmenopausal breast cancer with anastrozole would have a better clinical efficacy. The preoperative neoadjuvant endocrine treatment with anastrozole would be a better choice for the postmenopausal breast cancer patients which could not tolerate the chemotherapy.